Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aura Biosciences Inc
(NQ:
AURA
)
10.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aura Biosciences Inc
< Previous
1
2
3
4
Next >
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
August 09, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
Recap: Aura Biosciences Q1 Earnings
May 11, 2023
Via
Benzinga
Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate
February 16, 2023
Via
Benzinga
Why Shares of Aura Biosciences Jumped This Week
February 10, 2023
The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy.
Via
The Motley Fool
Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug
October 03, 2022
Via
Benzinga
Aura Biosciences to Participate in Upcoming Investor Conferences
May 24, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
May 12, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
May 11, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
March 15, 2023
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
February 16, 2023
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
February 09, 2023
From
Aura Biosciences Inc.
Via
Business Wire
$49.5 Million Bet On Howard Hughes? Check Out These 4 Stocks Insiders Are Buying
December 08, 2022
Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
December 01, 2022
Via
Benzinga
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
December 01, 2022
Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 01, 2022
Via
Benzinga
Aura Biosciences Announces Pricing of Public Offering of Common Stock
November 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Announces Proposed Public Offering of Common Stock
November 30, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
November 10, 2022
From
Aura Biosciences
Via
Business Wire
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
November 10, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
November 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Tesla, ABB And Other Big Losers From Monday
October 04, 2022
U.S. stocks closed sharply higher with the Dow Jones jumping more than 750 points on Monday. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 03, 2022
Gainers
Via
Benzinga
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
October 04, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...
Via
Benzinga
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
October 03, 2022
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
Via
Benzinga
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
October 03, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
September 28, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
September 27, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 14, 2022
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.